Pfizer (PFE) Accounts Payables (2009 - 2026)

Pfizer has disclosed Accounts Payables across 18 years of filings, most recently posting $4.5 billion for Q1 2026.

• In Q1 2026, Accounts Payables fell 14.01% year-over-year to $4.5 billion; the TTM figure through Mar 2026 stood at $4.5 billion (down 14.01% YoY), while the FY2025 annual figure was $5.2 billion, down 6.98% from the prior year.
• Accounts Payables fell to $4.5 billion in Q1 2026, from $5.2 billion in the prior quarter.
• Over the last five years, Accounts Payables for PFE reached as high as $6.8 billion in Q4 2022 and fell as low as $4.5 billion in Q1 2026.
• The 5-year median for Accounts Payables is $5.5 billion (2022), against an average of $5.6 billion.
• Annual changes were most pronounced in 2022 — Accounts Payables surged 43.47% — and 2024, when it declined 16.05%.
• A 5-year view of Accounts Payables shows it stood at $6.8 billion in 2022, then slipped by 1.45% to $6.7 billion in 2023, then decreased by 16.05% to $5.6 billion in 2024, then slipped by 6.98% to $5.2 billion in 2025, then decreased by 14.01% to $4.5 billion in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $4.5 billion, $5.2 billion, and $5.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.